These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 34766005)

  • 1. Fast and long-lasting immune response to S-trimer COVID-19 vaccine adjuvanted by PIKA.
    Liu Y; Dai L; Feng X; Gao R; Zhang N; Wang B; Han J; Zou Q; Guo X; Zhu H; Liu J; Qin C; Zhang Y; Bao L; Li M
    Mol Biomed; 2021; 2(1):29. PubMed ID: 34766005
    [TBL] [Abstract][Full Text] [Related]  

  • 2. High-Titer Neutralizing Antibodies against the SARS-CoV-2 Delta Variant Induced by Alhydroxyquim-II-Adjuvanted Trimeric Spike Antigens.
    Counoupas C; Pino P; Stella AO; Ashley C; Lukeman H; Bhattacharyya ND; Tada T; Anchisi S; Metayer C; Martinis J; Aggarwal A; Dcosta BM; Britton WJ; Kint J; Wurm MJ; Landau NR; Steain M; Turville SG; Wurm FM; David SA; Triccas JA
    Microbiol Spectr; 2022 Feb; 10(1):e0169521. PubMed ID: 35171046
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A recombinant receptor-binding domain in trimeric form generates protective immunity against SARS-CoV-2 infection in nonhuman primates.
    Yang L; Tian D; Han JB; Fan W; Zhang Y; Li Y; Sun W; Wei Y; Tian X; Yu DD; Feng XL; Cheng G; Bi Y; Zheng YT; Liu W
    Innovation (Camb); 2021 Aug; 2(3):100140. PubMed ID: 34179862
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Low-Dose SARS-CoV-2 S-Trimer with an Emulsion Adjuvant Induced Th1-Biased Protective Immunity.
    Liao HC; Wu WL; Chiang CY; Huang MS; Shen KY; Huang YL; Wu SC; Liao CL; Chen HW; Liu SJ
    Int J Mol Sci; 2022 Apr; 23(9):. PubMed ID: 35563292
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Elicitation of Broadly Neutralizing Antibodies against B.1.1.7, B.1.351, and B.1.617.1 SARS-CoV-2 Variants by Three Prototype Strain-Derived Recombinant Protein Vaccines.
    Yang Y; Zang J; Xu S; Zhang X; Yuan S; Wang H; Lavillette D; Zhang C; Huang Z
    Viruses; 2021 Jul; 13(8):. PubMed ID: 34452287
    [TBL] [Abstract][Full Text] [Related]  

  • 6. MPLA-Adjuvanted Liposomes Encapsulating S-Trimer or RBD or S1, but Not S-ECD, Elicit Robust Neutralization Against SARS-CoV-2 and Variants of Concern.
    Wang J; Yin XG; Wen Y; Lu J; Zhang RY; Zhou SH; Liao CM; Wei HW; Guo J
    J Med Chem; 2022 Feb; 65(4):3563-3574. PubMed ID: 35108485
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and breadth of adjuvanted SARS-CoV-2 receptor-binding domain nanoparticle vaccine in macaques.
    King HAD; Gordon Joyce M; Naouar IE; Ahmed A; Cincotta CM; Subra C; Peachman KK; Hack HH; Chen RE; Thomas PV; Chen WH; Sankhala RS; Hajduczki A; Martinez EJ; Peterson CE; Chang WC; Choe M; Smith C; Headley JA; Elyard HA; Cook A; Anderson A; Wuertz KM; Dong M; Swafford I; Case JB; Currier JR; Lal KG; Amare MF; Dussupt V; Molnar S; Daye SP; Zeng X; Barkei EK; Alfson K; Staples HM; Carrion R; Krebs SJ; Paquin-Proulx D; Karasavvas N; Polonis VR; Jagodzinski LL; Vasan S; Scott PT; Huang Y; Nair MS; Ho DD; de Val N; Diamond MS; Lewis MG; Rao M; Matyas GR; Gromowski GD; Peel SA; Michael NL; Modjarrad K; Bolton DL
    bioRxiv; 2021 Apr; ():. PubMed ID: 33851155
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Function is more reliable than quantity to follow up the humoral response to the Receptor Binding Domain of SARS- CoV-2 Spike protein after natural infection or COVID-19 vaccination.
    Sariol CA; Pantoja P; Serrano-Collazo C; Rosa-Arocho T; Armina A; Cruz L; Stone ET; Arana T; Climent C; Latoni G; Atehortua D; Pabon-Carrero C; Pinto AK; Brien JD; Espino AM
    medRxiv; 2021 Aug; ():. PubMed ID: 34100029
    [TBL] [Abstract][Full Text] [Related]  

  • 9. SARS-CoV-2 RBD trimer protein adjuvanted with Alum-3M-052 protects from SARS-CoV-2 infection and immune pathology in the lung.
    Routhu NK; Cheedarla N; Bollimpelli VS; Gangadhara S; Edara VV; Lai L; Sahoo A; Shiferaw A; Styles TM; Floyd K; Fischinger S; Atyeo C; Shin SA; Gumber S; Kirejczyk S; Dinnon KH; Shi PY; Menachery VD; Tomai M; Fox CB; Alter G; Vanderford TH; Gralinski L; Suthar MS; Amara RR
    Nat Commun; 2021 Jun; 12(1):3587. PubMed ID: 34117252
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comprehensive mapping of neutralizing antibodies against SARS-CoV-2 variants induced by natural infection or vaccination.
    Chen X; Chen Z; Azman AS; Sun R; Lu W; Zheng N; Zhou J; Wu Q; Deng X; Zhao Z; Chen X; Ge S; Yang J; Leung DT; Yu H
    medRxiv; 2021 May; ():. PubMed ID: 33972950
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Single Immunization with Recombinant ACAM2000 Vaccinia Viruses Expressing the Spike and the Nucleocapsid Proteins Protects Hamsters against SARS-CoV-2-Caused Clinical Disease.
    Deschambault Y; Lynch J; Warner B; Tierney K; Huynh D; Vendramelli R; Tailor N; Frost K; Sajesh B; LeBlanc K; Layne C; Lin L; Tamming L; Beniac D; Booth S; Carpenter M; Safronetz D; Li X; Kobasa D; Cao J
    J Virol; 2022 May; 96(9):e0038922. PubMed ID: 35412347
    [TBL] [Abstract][Full Text] [Related]  

  • 12. SARS-CoV-2 Spike Protein Stabilized in the Closed State Induces Potent Neutralizing Responses.
    Carnell GW; Ciazynska KA; Wells DA; Xiong X; Aguinam ET; McLaughlin SH; Mallery D; Ebrahimi S; Ceron-Gutierrez L; Asbach B; Einhauser S; Wagner R; James LC; Doffinger R; Heeney JL; Briggs JAG
    J Virol; 2021 Jul; 95(15):e0020321. PubMed ID: 33963055
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluating the Neutralizing Ability of a CpG-Adjuvanted S-2P Subunit Vaccine Against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Variants of Concern.
    Lien CE; Kuo TY; Lin YJ; Lian WC; Lin MY; Liu LT; Cheng J; Chou YC; Chen C
    Clin Infect Dis; 2022 Jun; 74(11):1899-1905. PubMed ID: 34739037
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sterilizing Immunity against SARS-CoV-2 Infection in Mice by a Single-Shot and Modified Imidazoquinoline TLR7/8 Agonist-Adjuvanted Recombinant Spike Protein Vaccine.
    Jangra S; De Vrieze J; Choi A; Rathnasinghe R; Laghlali G; Uvyn A; Van Herck S; Nuhn L; Deswarte K; Zhong Z; Sanders N; Lienenklaus S; David S; Strohmeier S; Amanat F; Krammer F; Hammad H; Lambrecht BN; Coughlan L; García-Sastre A; De Geest BG; Schotsaert M
    bioRxiv; 2020 Oct; ():. PubMed ID: 33106810
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety and Efficacy of Combined Intramuscular/Intranasal RAZI-COV PARS Vaccine Candidate Against SARS-CoV-2: A Preclinical Study in Several Animal Models.
    Banihashemi SR; Es-Haghi A; Fallah Mehrabadi MH; Nofeli M; Mokarram AR; Ranjbar A; Salman M; Hajimoradi M; Razaz SH; Taghdiri M; Bagheri M; Dadar M; Hassan ZM; Eslampanah M; Salehi Najafabadi Z; Lotfi M; Khorasani A; Rahmani F
    Front Immunol; 2022; 13():836745. PubMed ID: 35693788
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A human cell-based SARS-CoV-2 vaccine elicits potent neutralizing antibody responses and protects mice from SARS-CoV-2 challenge.
    He X; Ding L; Cao K; Peng H; Gu C; Li Y; Li D; Dong L; Hong X; Wang X; Fu M; Qiu C; Zhu C; Zhang Z; Song S; Wang C; Jiang Z; Xie Y; Qi Z; Zhao C; Zhao P; Zhang X; Xu J
    Emerg Microbes Infect; 2021 Dec; 10(1):1555-1573. PubMed ID: 34304724
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Protein-based SARS-CoV-2 spike vaccine booster increases cross-neutralization against SARS-CoV-2 variants of concern in non-human primates.
    Pavot V; Berry C; Kishko M; Anosova NG; Huang D; Tibbitts T; Raillard A; Gautheron S; Gutzeit C; Koutsoukos M; Chicz RM; Lecouturier V
    Nat Commun; 2022 Mar; 13(1):1699. PubMed ID: 35361754
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Function Is More Reliable than Quantity to Follow Up the Humoral Response to the Receptor-Binding Domain of SARS-CoV-2-Spike Protein after Natural Infection or COVID-19 Vaccination.
    Sariol CAA; Pantoja P; Serrano-Collazo C; Rosa-Arocho T; Armina-Rodríguez A; Cruz L; Stone ETT; Arana T; Climent C; Latoni G; Atehortua D; Pabon-Carrero C; Pinto AKK; Brien JDD; Espino AMM
    Viruses; 2021 Sep; 13(10):. PubMed ID: 34696403
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Recognition of Variants of Concern by Antibodies and T Cells Induced by a SARS-CoV-2 Inactivated Vaccine.
    Melo-González F; Soto JA; González LA; Fernández J; Duarte LF; Schultz BM; Gálvez NMS; Pacheco GA; Ríos M; Vázquez Y; Rivera-Pérez D; Moreno-Tapia D; Iturriaga C; Vallejos OP; Berríos-Rojas RV; Hoppe-Elsholz G; Urzúa M; Bruneau N; Fasce RA; Mora J; Grifoni A; Sette A; Weiskopf D; Zeng G; Meng W; González-Aramundiz JV; González PA; Abarca K; Ramírez E; Kalergis AM; Bueno SM
    Front Immunol; 2021; 12():747830. PubMed ID: 34858404
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cross-Neutralization of Emerging SARS-CoV-2 Variants of Concern by Antibodies Targeting Distinct Epitopes on Spike.
    Changrob S; Fu Y; Guthmiller JJ; Halfmann PJ; Li L; Stamper CT; Dugan HL; Accola M; Rehrauer W; Zheng NY; Huang M; Wang J; Erickson SA; Utset HA; Graves HM; Amanat F; Sather DN; Krammer F; Kawaoka Y; Wilson PC
    mBio; 2021 Dec; 12(6):e0297521. PubMed ID: 34781736
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.